BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
These findings suggest CNS tumors with BRAF(V600E</span>) are autophagy-dependent and that identification of BRAF(V600E) may be a marker to identify pediatric patients with the best potential response to autophagy inhibition.
These findings</span> suggest that CNS tumorswith BRAF(V600E) are autophagy-dependent and should be targeted with autophagy inhibition in combination with other therapeutic strategies.
BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes.